

# CANCER GENOMICS & PROTEOMICS

**Published by the International Institute  
of Anticancer Research**

ISSN: 1109-6535

**Volume 2, 2005**



## Editorial Board

- A. Seth** Editor-in-Chief  
Laboratory of Molecular Pathology, Sunnybrook and Women's CHSC,  
Toronto, ON, Canada
- J.G. Delinassios** Managing Editor and Executive Publisher,  
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland  
**S. Aaronson** Derarld H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY, USA  
**J.D. Aitchison** Institute for Systems Biology, Seattle, WA, USA  
**W. Ansorge** IAET, Borex, Switzerland  
**S. Antonarakis** Division of Medical Genetics, University of Geneva Medical School, Switzerland  
**F.G. Barr** Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA  
**A.M. Chinnaiyan** Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA  
**B.F.C. Clark** Department of Molecular Biology, University of Aarhus, Denmark  
**R. Clarke** Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA  
**I. Dunham** The Wellcome Trust Sanger Centre, Wellcome Trust Genome Campus, Cambridge, UK  
**N.A. Ellis** Department of Human Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA  
**J.A. Fernandes-Pol** Metalloproteomics, LLC, Chesterfield, MO, USA  
**C.V. Forst** McClintock Resource, Bioscience Division, Los Alamos National Laboratory, NM, USA  
**M. Fountoulakis** F. Hoffman - La Roche Pharmaceutical Research, Basel, Switzerland  
**W.L. Gerald** Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA  
**J.W. Gray** Cancer Genetics Program, Comprehensive Cancer Center, University of California San Francisco, CA, USA  
**B.B. Haab** Van Andel Research Institute, Grand Rapids, MI, USA  
**J.D. Hoheisel** Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany  
**R.P. Huang** Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA  
**T.H.M. Huang** Comprehensive Cancer Center, Human Cancer Genetics Program, Ohio State University, Columbus, OH, USA
- Yasumasa Ito** Orthopedic Division, National Cancer Center Hospital, Tokyo, Japan  
**Yoshiaki Ito** Institute of Molecular and Cell Biology, Clinical Research Centre, Singapore  
**V.C. Jordan** Diana, Princess of Wales Cancer Research Department, Lynn Sage Breast Cancer Research Program, Northwestern University Medical School, Chicago, IL, USA
- A. Kallioniemi** Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland  
**O.P. Kallioniemi** Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland  
**M. Kanehisa** Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan  
**S.E. Kern** Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD, USA  
**K. Khalili** College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
- S.D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece  
**P. Lichter** Deutsches Krebsforschungszentrum, Heidelberg, Germany  
**G. Lubec** Department of Pediatrics, University of Vienna, Austria  
**P.J. McCormick** Center for Comp. Functional Genomics, VA Medical Center University at Albany, SUNY, Rensselaer, NY, USA
- J.D. Minna** Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA
- F. Mitelman** Department of Clinical Genetics, University Hospital, Lund, Sweden  
**P. Nelson** Fred Hutchinson Cancer Research Center, Seattle, WA, USA

- R. Ohlsson** Department of Development and Genetics, Evolution Biology Center, Uppsala University, Sweden  
**I. Pastan** Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA  
**J. Quackenbush** The Institute of Genomic Research, Rockville, MD, USA  
**G. Rechavi** Pediatric Hemato-Oncology Department, Sheba Medical Center, Tel-Hashomer, Israel  
**R.H. Reeves** Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA  
**K.L. Reichelt** Institute of Pediatric Research, The National Hospital, University of Oslo, Norway  
**T. Ried** Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA  
**K.D. Rodland** Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA  
**C. Sansom** The School of Crystallography, Birbeck College, University of London, UK  
**Y. Sakaki** Human Genome Research Group, RIKEN Genomic Sciences Center, Yokohama, Japan  
**N.A. Saunders** Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia  
**S.W. Scherer** The Hospital for Sick Children, Department of Genetics, University of Toronto, ON, Canada  
**G.V. Sherbet** University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK  
**Y. Shimonishi** Nagahama Institute of Bioscience and Technology, Shiga, Japan  
**S. Smith** City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA  
**D. Sudar** Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA, USA  
**A.-C. Syvänen** Department of Medical Sciences, Uppsala University Hospital, Sweden  
**K. Tanaka** Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan  
**J.M. Trent** Tgen, Phoenix, AZ, USA  
**G. Tsangaris** Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics- Proteomics, Athens, Greece  
**L.-C. Tsui** The Hospital for Sick Children, University of Toronto, ON, Canada  
**A. Ullrich** Department of Molecular Biology, Max-Planck Institute of Biochemistry, Martinsried, Germany  
**G.F. Vande Woude** Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA  
**D.K. Watson** Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA  
**K. Williams** Keck Laboratory, Department of Molecular Biophysics and Biochemistry, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS, EMBASE and BIOBASE (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal.

**Editorial Office:**

International Institute of Anticancer Research  
 1st km Kapandritiou-Kalamou Road,  
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.  
 Tel: 0030 22950 52945, Fax: 0030 22950 53389  
 e-mail: journals@iiar-anticancer.org. Website: www.iiar-anticancer.org

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel.: 0030 22950 52945, Fax: 0030 22950 53389, e-mail (Editorial Office): journals@iiar-anticancer.org. e-mail (Managing Editor): editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook and Women's College Health Sciences Center, 2075 Bayview Avenue, Room E-423, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

## Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 2, 2005.

AACR-Cancer Research Foundation, U.S.A.	Hospital Privado de Comunidad, Mar del Plata, Argentina
Association de la Recherche contre le Cancer, France	Ireland's Higher Educational Authority Program
Association Nationale de la Recherche Technique, France	Korea Ministry of Science and Technology
Austrian Embassy Development Cooperation, Addis Ababa, Ethiopia	Medical Research Council, U.K.
Berliner Krebsgesellschaft e.V., Berlin, Germany	Metalloproteomics LLC, Chesterfield, MO, U.S.A.
Cancer Society, Stockholm, Sweden	Ministère des Finances et de l'Industrie, France
Centre of Excellence in Molecular Medicine MolMed, European Commission	Misses Barrie Charitable Trust, U.K.
Crafoord Foundation, Sweden	National Cancer Institute, U.S.A.
Department of Defense, U.S.A.	National Office for Research and Technology, Hungary
DVA Medical Center, U.S.A.	National Science Council, Taiwan, R.O.C.
Elsa Pardee Foundation, U.S.A.	Norwegian Research Council
European Union	Oligene GmbH, Berlin, Germany
Felleslegatet til Fordel	Roswell Park Alliance Foundation, U.S.A.
Fondo de Investigación Sanitaria, Spain	The King Gustav V Jubilee Fund, Stockholm, Sweden
G. Nilsson Cancer Foundation, Sweden	The Ralph C. Wilson Sr. and Ralph C. Wilson Jr. Medical Research Foundation, U.S.A.
German Academic Exchange Service	The Swedish Cancer Society
German Ministry of Education and Science	UICC International Cancer Technology Transfer Fellowship

## Contents, Volume 2, 2005

### Number 1

Genomics, Proteomics and Cancer: Specific Ribosomal, Mitochondrial, and Tumor Reactive Proteins can be Used as Biomarkers for Early Detection of Breast Cancer in Serum. J. ALBERTO FERNANDEZ-POL, PAUL D. HAMILTON, DENNIS J. KLOS ( <i>Chesterfield, MO, U.S.A.</i> ).....	1
A Display Thiol-Proteomics Approach to Characterize Global Redox Modification of Proteins by Selenium: Implications for the Anticancer Action of Selenium. E-M. PARK, K-S. CHOI, S-Y. PARK, E-S. KONG, K. ZU, Y. WU, H.O ZHANG, C. IP, Y-M. PARK ( <i>Buffalo, NY, U.S.A.; Incheon, Korea</i> ) .....	25
* Protein Microarrays – A Promising Tool for Cancer Diagnosis. N. SCHNEIDERHAN-MARRA, A. KIRN, A. DÖTTINGER, M. TEMPLIN, G. SAUER, H. DEISSLER, T.O. JOOS ( <i>Ulm; Reutlingen, Germany</i> ).....	37
Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. L. O'DRISCOLL, E. KENNY, M. PEREZ DE VILLARREAL, M. CLYNES ( <i>Dublin, Ireland</i> ).....	43
Metallopanstimulin / S27 Ribosomal Antigen Expression in Stages I and II Breast Cancer: its Relationship with Clinicopathologic Factors. A.S. SUNDBLAD, L. RICCI, F.P. XYNOS, J. ALBERTO FERNANDEZ-POL ( <i>Chesterfield, MO, U.S.A.</i> ) .....	53

### Number 2

Combined Oligonucleotide and Protein Microarray Temporal Analysis of p53-mediated Apoptosis. A.P. BLACK, E. WEE, T. LAMBE, A. BAILEY, L. JONES, G.S. OGG ( <i>Oxford, U.K.</i> ).....	61
* A Functional Genomic Approach for Screening Preneoplastic Stages of Sporadic Colon Cancer. F.E. AHMED ( <i>Greenville, NC, U.S.A.</i> ).....	71
Microarray-based Analyses of Hypoxia-induced Transcriptional Changes in Breast Cancer Cell Lines. I. HEDENFALK, N. GLARNER, A. KRONBLAD, S. VEERLA, M. RINGNÉR, G. LANDBERG ( <i>Lund, Sweden</i> ) .....	83
Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. H. ZHANG, Y. DONG, H. ZHAO, J.D. BROOKS, L. HAWTHORN, N. NOWAK, J.R. MARSHALL, A.C. GAO, C. IP ( <i>Buffalo, NY; Stanford, CA, U.S.A.</i> ).....	97
Molecular Determinants of Response of Tumor Cells to Berberine. T. EFFERTH, Z. CHEN, B. KAINA, GAN WANG ( <i>Heidelberg; Mainz, Germany; Guangzhou, P.R. China; Detroit, MI, U.S.A.</i> ) .....	115

### Number 3

Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis. S. MOHR, A. NEUVILLE, M.C. BOTTIN, J.C. MICILLINO, G. KEITH, B.H. RIHN ( <i>Strasbourg; Nancy, France</i> ) . . . . .	125
---	-----

* Using Comparative Genomics to Leverage Animal Models in the Identification of Cancer Genes. Examples in Prostate Cancer. M.W. DATTA, M.A. SUCKOW, S. TWIGGER, M. POLLARD, H. JACOB, P.J. TONELLATO ( <i>Atlanta, GA; Notre Dame, IN; Milwaukee, WI, U.S.A.</i> ) . . . . .	137
Down-regulation of <i>BRMS1</i> mRNA Expression in Breast Cancer is not Related to the Presence of Axillary Node Metastasis. F. GÓMEZ-ESQUER, D. AGUDO, F. MARTÍNEZ-ARRIBAS, G. DÍAZ-GIL, M. POLLÁN, J. SCHNEIDER ( <i>Madrid, Spain</i> ) . . . . .	145
Proteomic Analysis of Bladder Cancer Cells Reveals Potential Candidates of Biomarkers in Bladder Tumorigenesis T.-F. WU, H. WU, N.-H. CHOW, C.-F. LIAO, H.-S. LIU ( <i>Tainan, Taiwan, R.O.C.</i> ) . . . . .	151
Abstracts of the First International Conference of the Hellenic Proteomics Society . . . . .	159

## Number 4

Proteomic Analysis of Membrane-associated Proteins from the Breast Cancer Cell Line MCF7. C. PIONNEAU, L. CANELLE, J. BOUSQUET, J. HARDOUIN, J. BIGEARD, M. CARON, R. JOUBERT-CARON ( <i>Bobigny; Marcy l'Etoile, France</i> ).....	199
Specific Expression of Potential Tumour Marker Proteins, Similar to No On or Off Transient A and HIRA-interacting Protein 5, in Mouse N1E-115 Neuroblastoma Cell Line. J-E. OH, E. ENGIDAWORK, J.-H. SHIN, G. LUBEC ( <i>Vienna, Austria; Addis Ababa, Ethiopia</i> ) .....	209
Biomarkers for Sensitivity to Docetaxel and Paclitaxel in Human Tumor Cell Lines <i>In Vitro</i> . E. IZBICKA, D. CAMPOS, G. CARRIZALES, A. TOLCHER ( <i>San Antonio, TX, U.S.A.</i> ).....	219
* Stathmin in Cell Proliferation and Cancer Progression. G.V. SHERBET, F. CAJONE ( <i>Newcastle-upon-Tyne, U.K.; Huntington Beach, CA, U.S.A.; Milan, Italy</i> ).....	227
The Cell Cycle Regulators <i>P16<sup>INK4a</sup></i> , <i>P15<sup>INK4b</sup></i> and Cyclin D1: Relationship to Clinicopathological Parameters and Disease-free Survival in Laryngeal Carcinoma Patients. E. EL-SALAHY, A.H. ABOU-GHALIA, A. ADLI, S.K. KASSIM ( <i>Cairo, Egypt</i> ) .....	239
* Tumor Suppressor Genes on Human Chromosome 3 and Cancer Pathogenesis. S. INGVARSSON ( <i>Reykjavik, Iceland</i> ).....	247

## Number 5

* Application of Microarrays for the Prediction of Therapy Response in Breast Cancer. B. GYÖRFFY, P. SUROWIAK, H. LAGE ( <i>Berlin, Germany; Budapest, Hungary; Wroclaw, Poland</i> ).....	255
Expression of Integrins and Adhesive Properties of Human Endothelial Cell Line EA.hy 926. P. BARANSKA, H. JERCZYNSKA, Z. PAWLOWSKA, W. KOZIOLKIEWICZ, C.S. CIERNIEWSKI ( <i>Lodz, Poland</i> ) .....	265
The Protein Profile of the Human Immature T-cell Line CCRF-CEM. A.K. ANAGNOSTOPOULOS, K. VOUGAS, A. KOLIALEXI, A. MAVROU, M. FOUNTOULAKIS, G.T. TSANGARIS ( <i>Athens, Greece</i> ) .....	271
* Phylogenetics: Applications, Software and Challenges. A. STAMATAKIS ( <i>Heraklion, Greece</i> ).....	301

**Number 6**

Genomic Instability, DNA Alterations and Tumor Eosinophilic Expression in Head and Neck Squamous Cell Carcinoma. S.J. ALRAWI, D. STOLER, D. TAN, M. DAYTON, T. LOREE, J.F. GIBBS, N. RIGUAL, S. SAIT, T. KHOURY, W. HICKS JR, G. ANDERSON ( <i>Buffalo, NY, U.S.A.</i> ).....	307
* Quantitative Real-time RT-PCR: Application to Carcinogenesis. F.E. AHMED ( <i>Greenville, NC, U.S.A.</i> ) .....	317
Tissue Profiling by MALDI Mass Spectrometry Distinguishes Clinical Grades of Soft Tissue Sarcomas. R.L. CALDWELL, G.E. HOLT, R.M. CAPRIOLI ( <i>Nashville, TN, U.S.A.</i> ) .....	333
Proteomic Analysis of a Human Prostate Cancer Cell Line after Incubation with a Novel Somatostatin14 Derivative. Z. LIU, M. MARQUEZ, S. NILSSON, A.R. HOLMBERG, A. ALAIYA ( <i>Stockholm, Sweden; Jinan, China</i> ) .....	347
Tumour-associated Proteins in Oral Squamous Cell Carcinomas by Proteomics. S.O. IBRAHIM, T. MIRON, M. KROHN, A.N. AMARATUNGA, S. WARNAKULASAURIYA, E. N. VASSTRAND ( <i>Bergen; Oslo, Norway; Rehovot, Israel; Peradeniya, Sri Lanka; London, U.K.</i> ) .....	353
<b>Volume 2, 2005, Index</b> .....	365-380
Reviews (pages 37, 71, 137, 227, 247, 255, 301, 317)	

## Subject Index

(Figures refer to page numbers)

- ABC transporters, berberine, cluster analysis, DNA repair, microarray analysis, multidrug resistance, 115
- Adhesive properties, endothelial cells, VEGF, 265
- Androgen receptor, selenium, chemoprevention, prostate carcinogenesis, 97
- Animal models, cancer genes, prostate cancer, comparative genomics, review, 137
- Antibody microarrays, mass spectrometry, protein profiling, matrix-assisted laser desorption, ionization time of flight mass spectrometry, 353
- Apoptosis, p53, microarray, protein, mRNA, 61
- Bcl-2, docetaxel, paclitaxel, cancer, biomarker, 219
- Bead-based technology, protein microarray, sandwich immunoassays, breast cancer, review, 37
- Berberine, ABC transporters, cluster analysis, DNA repair, microarray analysis, multidrug resistance, 115
- Biomarker, docetaxel, paclitaxel, cancer, Bcl-2, 219
- Biomarker, MALDI mass spectrometry, proteomics, tissue profiling, soft tissue sarcoma, 333
- Biomarker, neuroblastoma cell line, no on or off transient A, HIRA-interacting protein 5, proteomics, 209
- Biomarker, proteomics, membrane proteins, breast cancer, 199
- Biomarkers, breast cancer, metallopanstimulin, 1
- Biomarkers, secreted mRNA, cancer, conditioned medium, serum/plasma, genomic profile, reverse transcriptase-polymerase chain reaction, 43
- BRCA1, breast cancer, hypoxia, HRE, microarray, 83
- Breast cancer, biomarker, proteomics, membrane proteins, 199
- Breast cancer, BRCA1, hypoxia, HRE, microarray, 83
- Breast cancer, cDNA microarrays, drug resistance, differential gene expression, response prediction, review, 255
- Breast cancer, metallopanstimulin, biomarkers, 1
- Breast cancer, metastasis, BRMS1, 145
- Breast cancer, protein microarray, bead-based technology, sandwich immunoassays, review, 37
- Breast carcinoma, metallopanstimulin, ribosomal protein S27, zinc finger proteins, 53
- BRMS1, cancer, breast, metastasis, 145
- Cancer genes, prostate cancer, comparative genomics, animal models, review, 137
- Cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Cancer, docetaxel, paclitaxel, biomarker, Bcl-2, 219
- Cancer, secreted mRNA, conditioned medium, serum/plasma, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43
- CCRF-CEM, human, T-cell, proteomics, two-dimensional protein database, mass spectrometry, MALDI-MS, 271
- CDNA microarrays, breast cancer, drug resistance, differential gene expression, response prediction, review, 255
- Cell cycle regulation, cancer progression, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Cell motility, cancer progression, cell cycle regulation, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Cell proliferation, cancer progression, cell cycle regulation, cell motility, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- CER1, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, VHL, elimination test, review, 247
- Chemoprevention, selenium, prostate carcinogenesis, androgen receptor, 97
- Chromosome 3, tumor suppressor gene, FHIT, chromosome instability, mutation, FRA3B, VHL, CER1, elimination test, review, 247
- Chromosome instability, tumor suppressor gene, chromosome 3, FHIT, mutation, FRA3B, VHL, CER1, elimination test, review, 247
- Cluster analysis, ABC transporters, berberine, DNA repair, microarray analysis, multidrug resistance, 115
- Colorectal cancer, detection chemistry, gene expression, LCM, real-time PCR, review, 317
- Colorectal cancer, diagnosis, gene expression, microarrays, regulation, PCR, review, 71
- Comparative genomic hybridization, head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, eosinophilic index, fluorescence *in situ* hybridization, eosinophilic infiltrate, 307
- Comparative genomics, cancer genes, prostate cancer, animal models, review, 137
- Conditioned medium, secreted mRNA, cancer, serum/plasma, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43
- Cyclin D1, laryngeal carcinoma, disease-free survival, p16<sup>INK4a</sup>, p15<sup>INK4b</sup>, 239
- Detection chemistry, colorectal cancer, gene expression, LCM, real-time PCR, review, 317
- Diagnosis, colorectal cancer, gene expression, microarrays, regulation, PCR, review, 71
- Differential gene expression, breast cancer, cDNA microarrays, drug resistance, response prediction, review, 255
- Disease-free survival, laryngeal carcinoma, p16<sup>INK4a</sup>, p15<sup>INK4b</sup>, cyclin D1, 239
- DNA repair, ABC transporters, berberine, cluster analysis, microarray analysis, multidrug resistance, 115

- Docetaxel, paclitaxel, cancer, biomarker, Bcl-2, 219
- Drug resistance, breast cancer, cDNA microarrays, differential gene expression, response prediction, review, 255
- Elimination test, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, VHL, CER1, review, 247
- Endothelial cells, adhesive properties, VEGF, 265
- Eosinophilic index, head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, comparative genomic hybridization, fluorescence *in situ* hybridization, eosinophilic infiltrate, 307
- Eosinophilic infiltrate, head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, comparative genomic hybridization, eosinophilic index, fluorescence *in situ* hybridization, 307
- Extracellular matrix, cancer progression, cell cycle regulation, cell motility, cell proliferation, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- FHIT, tumor suppressor gene, chromosome 3, chromosome instability, mutation, FRA3B, VHL, CER1, elimination test, review, 247
- Fluorescence *in situ* hybridization, head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, comparative genomic hybridization, eosinophilic index, eosinophilic infiltrate, 307
- FRA3B, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, VHL, CER1, elimination test, review, 247
- Gene expression, colorectal cancer, detection chemistry, LCM, real-time PCR, review, 317
- Gene expression, colorectal cancer, diagnosis, microarrays, regulation, PCR, review, 71
- Genomic instability index, head and neck squamous cell carcinoma, genomic instability, oral cavity, comparative genomic hybridization, eosinophilic index, fluorescence *in situ* hybridization, eosinophilic infiltrate, 307
- Genomic instability, head and neck squamous cell carcinoma, genomic instability index, oral cavity, comparative genomic hybridization, eosinophilic index, fluorescence *in situ* hybridization, eosinophilic infiltrate, 307
- Genomic profile, secreted mRNA, cancer, conditioned medium, serum/plasma, biomarkers, reverse transcriptase-polymerase chain reaction, 43
- Growth factors, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Head and neck squamous cell carcinoma, genomic instability, genomic instability index, oral cavity, comparative genomic hybridization, eosinophilic index, fluorescence *in situ* hybridization, eosinophilic infiltrate, 307
- Heat shock proteins, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- HIRA-interacting protein 5, neuroblastoma cell line, no on or off transient A, proteomics, biomarker, 209
- HRE, BRCA1, breast cancer, hypoxia, microarray, 83
- Hypoxia, BRCA1, breast cancer, HRE, microarray, 83
- Immuno-resistance, mesothelioma, microarray, transcriptomics, lymphocyte, 125
- Invasion, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Ionization time of flight mass spectrometry, antibody microarrays, mass spectrometry, protein profiling, matrix-assisted laser desorption, 353
- Laryngeal carcinoma, disease-free survival, p16<sup>INK4a</sup>, p15<sup>INK4b</sup>, cyclin D1, 239
- LCM, colorectal cancer, detection chemistry, gene expression, real-time PCR, review, 317
- LNCAp cell line, proteomic analysis, somatostatin, 347
- Lymphocyte, immuno-resistance, mesothelioma, microarray, transcriptomics, 125
- MALDI mass spectrometry, proteomics, tissue profiling, biomarker, soft tissue sarcoma, 333
- MALDI-MS, human, T-cell, CCRF-CEM, proteomics, two-dimensional protein database, mass spectrometry, 271
- Mass spectrometry, antibody microarrays, protein profiling, matrix-assisted laser desorption, ionization time of flight mass spectrometry, 353
- Mass spectrometry, human, T-cell, CCRF-CEM, proteomics, two-dimensional protein database, MALDI-MS, 271
- Matrix-assisted laser desorption, antibody microarrays, mass spectrometry, protein profiling, ionization time of flight mass spectrometry, 353
- Membrane proteins, biomarker, proteomics, breast cancer, 199
- Mesothelioma, immuno-resistance, microarray, transcriptomics, lymphocyte, 125
- Metalloproteinase, breast cancer, biomarkers, 1
- Metalloproteinase, breast carcinoma, ribosomal protein S27, zinc finger proteins, 53
- Metastasis, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Metastasis, cancer, breast, BRMS1, 145
- Microarray analysis, ABC transporters, berberine, cluster analysis, DNA repair, multidrug resistance, 115
- Microarray, BRCA1, breast cancer, hypoxia, HRE, 83
- Microarray, immuno-resistance, mesothelioma, transcriptomics, lymphocyte, 125

- Microarray, p53, apoptosis, protein, mRNA, 61
- Microarrays, colorectal cancer, diagnosis, gene expression, regulation, PCR, review, 71
- Microtubule dynamics, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- mRNA, p53, apoptosis, microarray, protein, 61
- Multidrug resistance, ABC transporters, berberine, cluster analysis, DNA repair, microarray analysis, 115
- Mutation, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, FRA3B, VHL, CER1, elimination test, review, 247
- Neuroblastoma cell line, no on or off transient A, HIRA-interacting protein 5, proteomics, biomarker, 209
- Nm23, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Oral cavity, head and neck squamous cell carcinoma, genomic instability, genomic instability index, comparative genomic hybridization, eosinophilic index, fluorescence *in situ* hybridization, eosinophilic infiltrate, 307
- P15<sup>INK4b</sup>, laryngeal carcinoma, disease-free survival, p16<sup>INK4a</sup>, cyclin D1, 239
- P16<sup>INK4a</sup>, laryngeal carcinoma, disease-free survival, p15<sup>INK4b</sup>, cyclin D1, 239
- P53, apoptosis, microarray, protein, mRNA, 61
- Paclitaxel, docetaxel, cancer, biomarker, Bcl-2, 219
- PCR, colorectal cancer, diagnosis, gene expression, microarrays, regulation, review, 71
- Phylogenetic interference, RAxML, phylogenetic software, review, 301
- Phylogenetic software, phylogenetic interference, RAxML, review, 301
- Prognosis, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, S100A4, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Prostate cancer, cancer genes, comparative genomics, animal models, review, 137
- Prostate carcinogenesis, selenium, chemoprevention, androgen receptor, 97
- Protein microarray, bead-based technology, sandwich immunoassays, breast cancer, review, 37
- Protein profiling, antibody microarrays, mass spectrometry, matrix-assisted laser desorption, ionization time of flight mass spectrometry, 353
- Protein, p53, apoptosis, microarray, mRNA, 61
- Proteomic analysis, LNCaP cell-line, somatostatin, 347
- Proteomics, biomarker, membrane proteins, breast cancer, 199
- Proteomics, human, T-cell, CCRF-CEM, two-dimensional protein database, mass spectrometry, MALDI-MS, 271
- Proteomics, MALDI mass spectrometry, tissue profiling, biomarker, soft tissue sarcoma, 333
- Proteomics, neuroblastoma cell line, no on or off transient A, HIRA-interacting protein 5, biomarker, 209
- Proteomics, transitional cell carcinoma, 151
- RAxML, phylogenetic interference, phylogenetic software, review, 301
- Real-time PCR, colorectal cancer, detection chemistry, gene expression, LCM, review, 317
- Redox modification, thiol-proteomics, selenium anticancer action, 25
- Regulation, colorectal cancer, diagnosis, gene expression, microarrays, PCR, review, 71
- Response prediction, breast cancer, cDNA microarrays, drug resistance, differential gene expression, review, 255
- Reverse transcriptase-polymerase chain reaction, secreted mRNA, cancer, conditioned medium, serum/plasma, genomic profile, biomarkers, 43
- Review, breast cancer, cDNA microarrays, drug resistance, differential gene expression, response prediction, 255
- Review, cancer genes, prostate cancer, comparative genomics, animal models, 137
- Review, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, tumour promoter genes, 227
- Review, colorectal cancer, detection chemistry, gene expression, LCM, real-time PCR, 317
- Review, colorectal cancer, diagnosis, gene expression, microarrays, regulation, PCR, 71
- Review, phylogenetic interference, RAxML, phylogenetic software, 301
- Review, protein microarray, bead-based technology, sandwich immunoassays, breast cancer, 37
- Review, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, VHL, CER1, elimination test, 247
- Ribosomal protein S27, breast carcinoma, metalloproteinase, zinc finger proteins, 53
- S100A4, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, signal transduction, suppressor genes, tumour promoter genes, review, 227
- Sandwich immunoassays, protein microarray, bead-based technology, breast cancer, review, 37
- Secreted mRNA, cancer, conditioned medium, serum/plasma, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43
- Selenium anticancer action, thiol-proteomics, redox modification, 25
- Selenium, chemoprevention, prostate carcinogenesis, androgen receptor, 97

- Serum/plasma, secreted mRNA, cancer, conditioned medium, genomic profile, biomarkers, reverse transcriptase-polymerase chain reaction, 43
- Signal transduction, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, suppressor genes, tumour promoter genes, review, 227
- Soft tissue sarcoma, MALDI mass spectrometry, proteomics, tissue profiling, biomarker, 333
- Somatostatin, proteomic analysis, LNCaP cell line, 347
- Suppressor genes, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, tumour promoter genes, review, 227
- T-cell, human, CCRF-CEM, proteomics, two-dimensional protein database, mass spectrometry, MALDI-MS, 271
- Thiol-proteomics, redox modification, selenium anticancer action, 25
- Tissue profiling, MALDI mass spectrometry, proteomics, biomarker, soft tissue sarcoma, 333
- Transcriptomics, immunoresistance, mesothelioma, microarray, lymphocyte, 125
- Transitional cell carcinoma, proteomics, 151
- Tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, VHL, CER1, elimination test, review, 247
- Tumour promoter genes, cancer progression, cell cycle regulation, cell motility, cell proliferation, extracellular matrix, growth factors, heat shock proteins, invasion, metastasis, microtubule dynamics, nm23, prognosis, S100A4, signal transduction, suppressor genes, review, 227
- Two-dimensional protein database, human, T-cell, CCRF-CEM, proteomics, mass spectrometry, MALDI-MS, 271
- VEGF, endothelial cells, adhesive properties, 265
- VHL, tumor suppressor gene, chromosome 3, FHIT, chromosome instability, mutation, FRA3B, CER1, elimination test, review, 247
- Zinc finger proteins, breast carcinoma, metalloproteinase, ribosomal protein S27, 53

## Authors Index

(Figures refer to page numbers)

- Abou-Ghalia AH, 239  
 Adli A, 239  
 Agudo D, 145  
 Ahmed FE, 71, 317  
 Alaiya A, 347  
 Alrawi SJ, 307  
 Amaratunga AN, 353  
 Anagnostopoulos AK, 271  
 Anderson G, 307  
 Bailey A, 61  
 Baranska P, 265  
 Bigeard J, 199  
 Black AP, 61  
 Bottin MC, 125  
 Bousquet J, 199  
 Brooks JD, 97  
 Cajone F, 227  
 Caldwell RL, 333  
 Campos D, 219  
 Canelle L, 199  
 Caprioli RM, 333  
 Caron M, 199  
 Carrizales G, 219  
 Chen Z, 115  
 Choi K-S, 25  
 Chow N-H, 151  
 Cierniewski CS, 265  
 Clynes M, 43  
 Datta MW, 137  
 Dayton M, 307  
 De Villarreal MP, 43  
 Deissler H, 37  
 Dong Y, 97  
 Díaz-Gil G, 145  
 Döttinger A, 37  
 Efferth T, 115  
 El-Salahy E, 239  
 Engidawork E, 209  
 Fernandez-Pol JA, 1, 53  
 Fountoulakis M, 271  
 Gao AC, 97  
 Gibbs JF, 307  
 Glarner N, 83  
 Györfy B, 255  
 Gómez-Esquer F, 145  
 Hamilton PD, 1  
 Hardouin J, 199  
 Hawthorn L, 97  
 Hedenfalk I, 83  
 Hicks W Jr, 307  
 Holmberg AR, 347  
 Holt GE, 333  
 Ibrahim SO, 353  
 Ingvarsson S, 247  
 Ip C, 25, 97  
 Izbicka E, 219  
 Jacob H, 137  
 Jerczynska H, 265  
 Jones L, 61  
 Joos TO, 37  
 Joubert-Caron R, 199  
 Kaina B, 115  
 Kassim SK, 239  
 Keith G, 125  
 Kenny E, 43  
 Houry T, 307  
 Kirn A, 37  
 Klos DJ, 1  
 Kolialexi A, 271  
 Kong E-S, 25  
 Koziolkiewicz W, 265  
 Krohn M, 353  
 Kronblad A, 83  
 Lage H, 255  
 Lambe T, 61  
 Landberg G, 83  
 Liao C-F, 151  
 Liu H-S, 151  
 Liu Z, 347  
 Loree T, 307  
 Lubec G, 209  
 Marshall JR, 97  
 Martínez-Arribas F, 145  
 Mavrou A, 271  
 Micillino JC, 125  
 Miron T, 353  
 Mohr S, 125  
 Márquez M, 347  
 Neuville A, 125  
 Nilsson S, 347  
 Nowak N, 97  
 O'Driscoll L, 43  
 Ogg GS, 61  
 Oh J-E, 209  
 Park E-M, 25  
 Park S-Y, 25  
 Park Y-M, 25  
 Pawlowska Z, 265  
 Pionneau C, 199  
 Pollard M, 137  
 Pollán M, 145  
 Ricci L, 53  
 Rigual N, 307  
 Rihn BH, 125  
 Ringnér M, 83  
 Sait S, 307  
 Sauer G, 37  
 Schneider J, 145  
 Schneiderhan-Marra N, 37  
 Sherbet GV, 227  
 Shin J-H, 209  
 Stamatakis A, 301  
 Stoler D, 307  
 Suckow MA, 137  
 Sundblad AS, 53  
 Surowiak P, 255  
 Tan D, 307  
 Templin M, 37  
 Tolcher A, 219  
 Tonellato PJ, 137  
 Tsangaris GT, 271  
 Twigger S, 137  
 Vasstrand EN, 353  
 Veerla S, 83  
 Vougas K, 271  
 Wang G, 115  
 Warnakulasauriya S, 353  
 Wee E, 61  
 Wu H, 151  
 Wu T-F, 151  
 Wu Y, 25  
 Xynos FP, 53  
 Zhang H, 25, 97  
 Zhao H, 97  
 Zu K, 25



## Instructions to Authors

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of application of genomic and proteomic technology to experimental and clinical cancer research. The journal's topical spectrum includes: (a) Molecular causes of carcinogenesis, cancer progression and metastasis; (b) Structural and functional aspects of genes in the cancer cell; (c) Advances in genomic and proteomic technologies applicable to cancer research; (d) Rational anticancer drug design and drug development.

CGP will also accept for publication abstracts and proceedings of scientific meetings, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to CGP will be subject to review, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are treated in confidence, without access to any person other than the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

**Copyright.** Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) Review articles concerning fields of recognizable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 2000 words, organized according to the following headings: Background - Materials and Methods - Results - Conclusions; (c) Introduction; (d) Materials and Methods, or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements, and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. A charge will be made for a colour plate.

**Tables.** Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. In the text, references should be cited by number.

Citations for the reference section of submitted works must be numbered consecutively. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2. McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for reproductive hormones* (O' Malley BW and Chamness GC, eds). New York, Plenum Publ Corp, 1973, pp.133-136.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC-IUB", "Bergey's Manual of Determinative Bacteriology". The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), MIAME Standard for Microarray Data. Human gene symbols may be obtained from HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations will be preferable. If a new abbreviation is used it must be defined at its first usage.

**Ethical Policies and Standards.** CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. Research involving the use of human fetuses, fetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** An original and two copies of the manuscript (including all photographs and graphs) should be sent to: Dr. J.G. Delinassios, Managing Editor, Cancer Genomics and Proteomics, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O.B. 22, Attiki 19014, Greece.

A floppy disc, CD-ROM or ZIP-disc must also be submitted indicating the computer-processing program. Authors are invited to submit along with their manuscripts a short list of possible reviewers and any previous publications which could facilitate reviewing. Manuscripts should be accompanied by six adhesive labels with the name and address of the Author to whom correspondence should be sent. Only the original copy of the submitted manuscript will be returned to Authors upon rejection.

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

**Reprints.** Twenty-five copies of each communication will be provided free of charge. Additional copies may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

CANCER GENOMICS & PROTEOMICS supports (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

For more information about CANCER GENOMICS & PROTEOMICS, IAR and the Conferences please visit the IAR website: [www.iar-anticancer.org](http://www.iar-anticancer.org)

**Publication Data:** CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

**Copyright:** Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr John G. Delinassios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: 0030 22950 52945, Fax: 0030 22950 53389, e-mail (Editorial Office): [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org), e-mail (Managing Editor): [editor@iar-anticancer.org](mailto:editor@iar-anticancer.org)

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook and Women's College Health Sciences Center, 2075 Bayview Avenue, Room E-423, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

**Annual Subscription Rates 2004, 2005:** Institutional subscription: Euro 800 per volume. Personal subscription: Euro 400 per volume. Prices include rapid delivery and insurance.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Managing Editor, Athens, Greece and should be sent to the Editorial Office.

**Advertising:** Correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.